Akums Launches Novel Formulations For Patients With Gastrointestinal Disorders

New Delhi: Akums Drugs & Pharmaceuticals Ltd on Monday announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

“Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement.

Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed.

“We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement.

Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

Related Posts

  • Pharma
  • June 21, 2025
  • 130 views
Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

New Delhi: In a regulatory relief to the company, the Subject Expert Committee (SEC) under the Gastroenterology and Hepatology division of the Central Drugs Standard Control Organisation (CDSCO) has recommended…

  • Pharma
  • June 21, 2025
  • 144 views
In Punjab, 2 arrested with 6 kg heroin, pistol in cross-border drug bust

Punjab Police busted a cross-border drug smuggling racket with the arrest of two persons who were allegedly in touch with a Pakistan-based smuggler, a top police officer said on Saturday.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

In Punjab, 2 arrested with 6 kg heroin, pistol in cross-border drug bust

In Punjab, 2 arrested with 6 kg heroin, pistol in cross-border drug bust

CDSCO flags 186 drugs that fail to meet quality standards

CDSCO flags 186 drugs that fail to meet quality standards

Pristyn’s Hat Trick, transcends North pushing envelop to South of Vindhyas

Pristyn’s Hat Trick, transcends North pushing envelop to South of Vindhyas